Cagrilintide
MetabolicAlso known as AM833
Evidence tier
Regulator-reviewed human evidence
3 human trials · 1 review
- Researched since
- 2021
- Publications
- 93
- Mean purity
- 99.4%
- Vendors listing
- 15
Ascension Peptides shows the highest mean assayed purity for Cagrilintide at 100.0% across 1 lot record. Purity figures below come from the certificates named in each row.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2021 — 5 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
93 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.4% across 13 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.99 pts purity across lots, mean label deviation 4.4%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
15 of 15 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
12 of 13 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Cagrilintide?
A long-acting analogue of the hormone amylin, studied for effects on appetite and body weight, frequently in combination with GLP-1 receptor agonists.
Studied in published research for appetite regulation, weight loss and obesity.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Studied in human phase 1 and phase 2 trials, including combinations with semaglutide. PepIndex does not evaluate clinical significance and does not describe administration.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity — The New England journal of medicine (2025)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2025).
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes — The New England journal of medicine (2025)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2025).
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial — Lancet (London, England) (2021)
Peer-reviewed article indexed in PubMed, published in Lancet (London, England) (2021).
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial — Lancet (London, England) (2023)
Peer-reviewed article indexed in PubMed, published in Lancet (London, England) (2023).
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity — Cardiology in review (2024)
Peer-reviewed article indexed in PubMed, published in Cardiology in review (2024).
- Development of Cagrilintide, a Long-Acting Amylin Analogue — Journal of medicinal chemistry (2021)
Peer-reviewed article indexed in PubMed, published in Journal of medicinal chemistry (2021).
- Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis — Indian journal of endocrinology and metabolism (2024)
Peer-reviewed article indexed in PubMed, published in Indian journal of endocrinology and metabolism (2024).
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 — EBioMedicine (2025)
Peer-reviewed article indexed in PubMed, published in EBioMedicine (2025).
Indexed studies4 human-evidence of 4
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis — Meta-analysis, 2024
To evaluate the comparative efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults with type 2 diabetes. Systematic review and network meta-analysis. PubMed, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), and Embase from database inception to 19 August 2023. Eligible randomised controlled trials enrolled adults with type 2 diabetes who received GLP-1RA treatments and…
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity — Human — controlled trial, 2025
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the combination (known as CagriSema) on weight loss in persons with either overweight and coexisting conditions or obesity is unknown. In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-ma…
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes — Human — controlled trial, 2025
Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring. In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated h…
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial — Human — controlled trial, 2021
Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide is a long-acting amylin analogue under investigation for weight management. We assessed the dose-response relationship of cagrilintide regarding the effects on bodyweight, safety, and tolerability. We conducted a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial at 57 sites including hospitals, specialist clinics, and primary care centres in ten …
Evidence digest
What the research on Cagrilintide actually shows
The indexed literature on Cagrilintide includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Cagrilintide is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| Next Gen PeptidesISO/IEC 17025 | 93.897% | $4.00 (33%) | 3 | 98.4% | 1.9% | |
| Polaris PeptidesISO/IEC 17025 | 93.877% | — | 2 | 99.8% | 11.6% | |
| PeptidePlugs | 89.790% | — | 2 | 99.7% | 5.0% | |
| Hydro Research PeptidesISO/IEC 17025 | 88.289% | — | 1 | 99.7% | 3.6% | |
| Northline LabsISO/IEC 17025 | 8793% | $11.00 (92%) | 0 | — | — | |
| American PeptidesISO/IEC 17025 | 78.2100% | $17.00 (142%) | 0 | — | — | |
| Ascension Peptides | 78.186% | — | 1 | 100.0% | 1.5% | |
| Good Science Bio | 77.275% | $9.00 (75%) | 0 | — | — | |
| NeuroLabs Research | 76.486% | $12.99 (108%) | 1 | 99.9% | 6.6% | |
| Simple Peptide | 7489% | — | 1 | 99.7% | 0.3% | |
| Disguised Alpha | 73.370% | $9.00 (75%) | 0 | — | — | |
| Vertex Labs | 70.170% | — | 1 | 99.8% | 4.8% | |
| Mile High Compounds | 64.194% | $12.00 (100%) | 1 | 99.0% | 2.0% | |
| BioLongevity Labs | 63.974% | $17.00 (142%) | 0 | — | — | |
| Licensed Peptides | 63.489% | $21.60 (180%) | 0 | — | — |
Certificate records
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Source |
|---|---|---|---|---|---|---|---|---|
| Vertex Labs | 2608190855 | Freedom Diagnostics Testing | 10 mg | 10.48 mg | 4.8% | 99.8% | Vendor-published | |
| PeptidePlugs | 103-11-ZB | Freedom Diagnostics Testing | 10 mg | 9.78 mg | 2.2% | 99.6% | Vendor-published | |
| NeuroLabs Research | NL01-CAGR10R | Analysis FreedomDiagnostics | 5 mg | 5.33 mg | 6.6% | 99.9% | Vendor-published | |
| Hydro Research Peptides | HR-2026-2608 | ILS Laboratories | 5 mg | 5.18 mg | 3.6% | 99.7% | Vendor-published | |
| PeptidePlugs | 142-04-DK | Freedom Diagnostics Testing | 10 mg | 9.21 mg | 7.9% | 99.9% | Vendor-published | |
| Simple Peptide | CAGR-052026-4 | Laboratory | 10 mg | 9.97 mg | 0.3% | 99.7% | Vendor-published | |
| Next Gen Peptides | CG10-12 | ILS Laboratories | 10 mg | 10.24 mg | 2.4% | 99.8% | Vendor-published | |
| Next Gen Peptides | CG05-08 | ILS Laboratories | 5 mg | 5.12 mg | 2.4% | 99.3% | Vendor-published | |
| Next Gen Peptides | CGL10-13 | ILS Laboratories | 10 mg | 10.09 mg | 0.9% | 96.1% | Vendor-published | |
| Ascension Peptides | 01-01260229 | MZ Biolabs | 10 mg | 10.15 mg | 1.5% | 100.0% | Vendor-published | |
| Polaris Peptides | POL-C5-6 | TrustPointe Analytics LLC | 5 mg | 4.96 mg | 0.7% | 99.6% | Vendor-published | |
| Polaris Peptides | POL-C10-2 | TrustPointe Analytics LLC | 10 mg | 12.24 mg | 22.4% | 100.0% | Vendor-published | |
| Mile High Compounds | CAG-010-MH-03 | Mile High Compounds | 10 mg | 9.8 mg | 2.0% | 99.0% | Vendor-published |